Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.
Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes/
Today, the Ad Council in partnership with the U.S. Department of Health and Human Services, AdoptUSKids, and KBS launched new public service advertisements (PSAs) for the award-winning Adoption from Foster Care campaign. The new television and radio PSAs encourage the adoption of older youth from foster care.
Of the 428,000 youth under the age of 18 in the U.S. foster care system, 112,000 are currently waiting for adoptive families, according to the most recent Adoption and Foster Care Analysis and Reporting System (AFCARS) data. Since the project’s launch in 2002, more than 26,000 children who were once photo listed on the AdoptUSKids website have been placed with permanent families. However, older youth and teens have lower adoption rates than younger children, and they often wait longer to be adopted. Currently, of the 5,560 youth photo-listed on the website as available for adoption, 43% are between the ages of 15 and 18 years old.
To view the multimedia release go to:
http://www.multivu.com/players/English/7979251-ad-council-adoptuskids-adopt-from-foster-care/
Auto and tech companies are coming together to put driverless cars on the road. Data is what's powering the race. From design and manufacturing to safety and services, data is informing every step of the process towards fully autonomous vehicles. As transformative as they are, self-driving, connected cars are just one component in a much-larger data-collection network soon to be on the world's roads and highways.
What's the future of transportation look like with self-driving and human-driving cars side-by-side? How will the data--some estimates go as high as 1GB per second--from driverless cars be put to use?
To view the multimedia release go to:
http://www.multivu.com/players/English/7889731-bloomberg-western-digital-bgovdata/
In today’s always-on world, people are more digitally-connected than ever before – yet less connected to one another in meaningful ways. That’s why Murad®, the pioneering clinical skincare brand, is launching the EyesUp Campaign, a new initiative designed to educate people about the danger of digital-only relationships and the power of real-world human connection. Through the campaign, Murad is encouraging people around the world to go “EyesUp” and connect with one another in real life.
Renowned as the “Father of Internal Skincare,” Dr. Murad’s groundbreaking work and research over the past decade has centered on helping people cope with Cultural Stress™, or the stress of modern living. The hallmarks of Cultural Stress include digital dependency, the inability to disconnect from work, and lowered self-esteem due to increased social expectations.
To view the multimedia release go to:
https://www.multivu.com/players/English/7833456-murad-skincare-eyesup-campaign/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Milano Design Week is the setting for a collaborative, large-scale light installation by LG and Japanese designer Tokujin Yoshioka. Entitled TOKUJIN YOSHIOKA x LG: S.F_Senses of the Future, the impressive work seeks to illustrate humanity’s relationship with the natural world and to illuminate LG’s human-centric design philosophy, and will be on exhibit from 4-9 April at Superstudio Più in Milan.
The Exhibition offers visitors a feast for their senses and a taste of what the future holds by combining LG’s cutting-edge technology with Tokujin Yoshioka’s groundbreaking experimental design techniques. One part of the exhibition conveys the story of hope for the future through a commonplace object in people’s lives – the S.F chair. But these are no ordinary chairs, but ones borne of science fiction. A total of seventeen S.F chairs have been artfully ensconced with LG’s advanced OLED displays which measure only 15mm thick. The chairs are both static and dynamic because of the brilliant flashes emitted from the double-sided panels and portray a meditation on the blindingly fast speed of modern day life.
To view the multimedia release go to:
https://www.multivu.com/players/English/8074251-lg-milano-design-week/
At just nine miles wide and a marathon-run long (or 26 miles), roughly 16,000 people call Martha’s Vineyard home, but the population swells to 100,000 during the busiest summer months. On this island south of Cape Cod, local organizations like South Mountain Company – an integrated architecture, building, engineering, and renewable energy company – know that thoughtful, responsible use of natural and human resources is key to maintaining the island’s vitality and beauty.
“South Mountain Company is a worker cooperative which means our employees have an ownership stake in the business, giving them the means to make lasting, valuable change where we all live and work – and installing SunPower solar is one way we choose to make an impact,” said John Abrams, founder, CEO and president of South Mountain Company. “We believe that every property South Mountain Company designs and builds should be both attractive and low-impact, producing more energy than it consumes whenever possible.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7706156-sunpower-south-mountain-marthas-vineyard/
Today, the newly-developed Body Volume Indicator (BVI)™ was revealed as a modern day measure of body composition and weight distribution following a 10-year collaboration with Mayo Clinic experts who led extensive research on fat distribution, the importance of fat assessment and the limitations of the current standard of Body Mass Index (BMI). In conjunction with the development of BVI, BVI America LLC, a subsidiary of 3D measurement pioneer Select Research, announced the launch of the revolutionary BVI Pro tablet application, which will provide an easily accessible and affordable means for the professional community to use the new BVI measurement in everyday clinical use to assess health risks.
The potential benefits of using Body Volume as a new indicator of risks were presented on April 27 by Mayo Clinic researchers, BVI America and the University of Westminster. It draws on 10 years of rigorous research, testing and validation using several potential Body Volume indices. Now BVI, calculated as a ratio between total volume and abdominal volume, can be used as a supplement to the current measurement standard of BMI, which is based solely on height and weight. BVI is considered to be a more precise means of estimating weight distribution and the fat around the organs, which is not visible to the human eye and can lead to serious health conditions, such as diabetes and heart disease. The medical and professional community at large is invited to contribute to the continued development of BVI by downloading and using the BVI Pro tablet application with their patients and clients; anonymous data collected will be analyzed by Mayo Clinic, whose research and validation of BVI will continue.
To view the multimedia release go to:
https://www.multivu.com/players/English/8093051-bvi-america-body-volume-app-health-fitness/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Entry-level employees are becoming less proficient in the skills most needed to succeed in today’s workplace, according to a recent national survey of human resources (HR) managers responsible for hiring. The survey, sponsored by leading early education provider Primrose Schools®, revealed skills like adaptability, teamwork and problem solving are critical to workplace success. Yet, 70 percent of seasoned HR managers report that entry-level employees are rarely proficient in these skills.
According to the survey, critical thinking, problem solving, teamwork, self-control, adaptability and working memory – collectively referred to by educators as executive function skills – are more highly valued in entry-level candidates than technical abilities, academic background and other factors. And while respondents state that entry-level employees are rarely proficient in these skills, two-thirds say hiring entry-level employees with good executive function skills is a top priority for their company’s long-term success.
To view the multimedia release go to:
https://www.multivu.com/players/English/8014453-primrose-schools-early-childhood-career-success-survey/
What happens when human desire twists…bends…warps…mutates?
What happens when that desire is fed…or even starved?
In this sequel to the Bram Stoker Award-winning anthology, Editor Vince Liaguno assembles a literary pantheon from the LGBT and horror communities to explore the dark underbelly of desire.
From unrequited love and repressed lust to consuming grief and the unquenchable thirst of addiction…from unfathomable sexual undergrounds to unspeakable perversions creeping into everyday suburbia, these abominations of desire will leave you gasping for breath and your taste for terror satiated. Find out more at http://bit.ly/ UnspeakableHorror2 horror
Today, Johnson & Johnson, the world’s largest healthcare company, launches Johnson & Johnson Our Story at the Powerhouse and Johnson & Johnson Our Story to take visitors on a journey through time and around the world as they explore the stories behind more than 130 years of innovations that have changed the course of human health.
Johnson & Johnson Our Story at the Powerhouse is housed within the 1907-built Powerhouse—the oldest building on the company’s global headquarters campus in New Brunswick, New Jersey and an artifact in its own right.
To view the multimedia release go to:
https://www.multivu.com/players/English/8077331-jnj-our-story/
